ArticleFrontiers in oncology2025
Histomorphological development and progression of gastric intramucosal papillary adenocarcinoma-a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study is to elucidate the developmental process, progression patterns, and histomorphological features of gastric-type intramucosal papillary adenocarcinoma. Methods: This study employed a retrospective research method. Histological examination and immunohistochemical analyses were conducted on endoscopic biopsy samples and endoscopic submucosal dissection (ESD) specimens from 450 cases of superficial gastric epithelial lesions. Results: Atrophic changes in gastric foveolar epithelium, resulting from infectious, chemical, autoimmune, or genetic factors, were associated with a sequential process of tumorigenesis in gastric intramucosal papillary adenocarcinoma. This process involved two phases of compensatory epithelial proliferation followed by three distinct stages of neoplastic transformation. The initial compensatory phase was characterized histologically by papillary hyperplasia of the gastric crypt epithelium. The second phase, representing transitional or dysregulated proliferation, was observed as gastric surface epithelial-type adenoma. The first neoplastic stage was identified as gastric-type low-grade intraepithelial neoplasia, followed by high-grade intraepithelial neoplasia, and culminating in the third stage as gastric-type intramucosal papillary adenocarcinoma. The progression of these stages was delineated based on histopathological features and immunophenotypic profiles. Conclusion: Recognizing the histopathological and immunophenotypic features involved in the stepwise development of gastric-type papillary adenocarcinoma enhances the accuracy of clinical management and surveillance of neoplastic progression. This has significant implications for early intervention and prevention of gastric cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.